Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review,

  • ID: 3837890
  • Drug Pipelines
  • 70 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Ablynx NV
  • AlphaMab Co., Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Oncobiologics, Inc.
  • R-Pharm
  • MORE
Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016

Summary

‘Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- The report reviews Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Ablynx NV
  • AlphaMab Co., Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Oncobiologics, Inc.
  • R-Pharm
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) Overview

Therapeutics Development

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Stage of Development

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Therapy Area

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Indication

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Companies

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Universities/Institutes

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Companies Involved in Therapeutics Development

Ablynx NV

AlphaMab Co., Ltd

Amgen Inc.

Astellas Pharma Inc.

Clonz Biotech Private Limited

Intas Pharmaceuticals Ltd.

Oncobiologics, Inc.

R-Pharm

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Drug Profiles

ALX-0141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDRI-99/373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KN-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit RANKL for Bone Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RANKL for Osteoclastogenesis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Dormant Projects

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Featured News & Press Releases

Mar 30, 2016: Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment

Oct 12, 2015: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia In Postmenopausal Women With Osteoporosis

Oct 11, 2015: New Data Show Greater Bone Mineral Density Gains With Prolia Compared With Zoledronic Acid

Oct 06, 2015: Amgen To Present Data From Multiple Studies For Prolia On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting

Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease

Jun 01, 2015: Amgen Presents Phase 3 Data At ASCO Showing Prolia (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors

May 13, 2015: Amgen Presents Data At ASCO 2015 On Prolia

Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis

Sep 10, 2014: Amgen Announces 18 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting

Oct 04, 2013: Amgen Presents Data From Several Prolia Studies At ASBMR

Jun 11, 2013: Daiichi Sankyo Launches Pralia Subcutaneous Injection 60mg Syringe For Treatment Of Osteoporosis

Mar 25, 2013: Daiichi Sankyo Receives Japanese Approval For Manufacture And Marketing Of Pralia For Treatment Of Osteoporosis

Nov 21, 2012: Amgen Canada Provides New Safety Information For Prolia

Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR

Oct 14, 2012: Amgen Presents Several Sub-Analysis From Pivotal Phase III Prolia Fracture Trial At ASBMR 2012

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Ablynx NV, H2 2016

Pipeline by AlphaMab Co., Ltd, H2 2016

Pipeline by Amgen Inc., H2 2016

Pipeline by Astellas Pharma Inc., H2 2016

Pipeline by Clonz Biotech Private Limited, H2 2016

Pipeline by Intas Pharmaceuticals Ltd., H2 2016

Pipeline by Oncobiologics, Inc., H2 2016

Pipeline by R-Pharm, H2 2016

Dormant Projects, H2 2016 54List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Ablynx NV
  • AlphaMab Co., Ltd
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Oncobiologics, Inc.
  • R-Pharm
  • MORE
According to our recently published report 'Tumor Necrosis Factor Ligand Superfamily Member 11 – Pipeline Review, H2 2016'; Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the publisher says: Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) Tumor necrosis factor ligand superfamily member 11 or RANKL is a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. Binding of RANK/RANKL within an osteoclast will secrete tumor growth factor, which can ultimately increase tumor growth and bone destruction activity. This protein was shown to be a dendritic cell survival factor and is involved in the regulation of T cell-dependent immune response. This protein was shown to activate anti-apoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor 6 which indicated this protein may have a role in the regulation of cell apoptosis.

The report 'Tumor Necrosis Factor Ligand Superfamily Member 11 – Pipeline Review, H2 2016' outlays comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Ablynx NV
AlphaMab Co., Ltd
Amgen Inc.
Astellas Pharma Inc.
Clonz Biotech Private Limited
Intas Pharmaceuticals Ltd.
Oncobiologics, Inc.
R-Pharm
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll